- Home
- CDRE vs TSHA Comparison
CDRE vs TSHA Comparison
Compare CDRE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- TSHA
- Stock Information
- Founded
- CDRE 2012
- TSHA 2019
- Country
- CDRE United States
- TSHA United States
- Employees
- CDRE N/A
- TSHA N/A
- Industry
- CDRE Industrial Specialties
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- TSHA Health Care
- Exchange
- CDRE Nasdaq
- TSHA Nasdaq
- Market Cap
- CDRE 1.3B
- TSHA 1.3B
- IPO Year
- CDRE 2021
- TSHA 2020
- Fundamental
- Price
- CDRE $37.60
- TSHA $4.57
- Analyst Decision
- CDRE Buy
- TSHA Strong Buy
- Analyst Count
- CDRE 2
- TSHA 8
- Target Price
- CDRE $31.50
- TSHA $9.38
- AVG Volume (30 Days)
- CDRE 317.3K
- TSHA 11.2M
- Earning Date
- CDRE 11-05-2025
- TSHA 11-12-2025
- Dividend Yield
- CDRE 1.01%
- TSHA N/A
- EPS Growth
- CDRE N/A
- TSHA N/A
- EPS
- CDRE 0.93
- TSHA N/A
- Revenue
- CDRE $572,607,000.00
- TSHA $8,098,000.00
- Revenue This Year
- CDRE $12.55
- TSHA N/A
- Revenue Next Year
- CDRE $7.70
- TSHA N/A
- P/E Ratio
- CDRE $40.41
- TSHA N/A
- Revenue Growth
- CDRE 7.66
- TSHA N/A
- 52 Week Low
- CDRE $27.07
- TSHA $1.05
- 52 Week High
- CDRE $40.28
- TSHA $5.40
- Technical
- Relative Strength Index (RSI)
- CDRE 70.09
- TSHA 69.54
- Support Level
- CDRE $35.44
- TSHA $3.10
- Resistance Level
- CDRE $36.68
- TSHA $5.40
- Average True Range (ATR)
- CDRE 1.11
- TSHA 0.32
- MACD
- CDRE 0.15
- TSHA 0.17
- Stochastic Oscillator
- CDRE 93.48
- TSHA 66.85
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.